US 11,725,044 B2
Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity
Odile Duvaux, Nantes (FR); and Jean-Paul Soulillou, Nantes (FR)
Assigned to Xenothera, Nantes (FR)
Appl. No. 15/516,742
Filed by XENOTHERA, Nantes (FR)
PCT Filed Oct. 15, 2015, PCT No. PCT/EP2015/073892
§ 371(c)(1), (2) Date Apr. 4, 2017,
PCT Pub. No. WO2016/059161, PCT Pub. Date Apr. 21, 2016.
Claims priority of application No. 14306633 (EP), filed on Oct. 15, 2014.
Prior Publication US 2017/0240616 A1, Aug. 24, 2017
Int. Cl. C07K 16/08 (2006.01); A01K 67/027 (2006.01); C07K 16/06 (2006.01); C12P 21/00 (2006.01); C07K 16/12 (2006.01); C07K 16/10 (2006.01); A61K 39/00 (2006.01); C12N 9/10 (2006.01); C07K 16/44 (2006.01); C12N 9/02 (2006.01)
CPC C07K 16/08 (2013.01) [A01K 67/0276 (2013.01); C07K 16/06 (2013.01); C07K 16/10 (2013.01); C07K 16/12 (2013.01); C12P 21/005 (2013.01); C12Y 114/18002 (2013.01); C12Y 204/01087 (2013.01); A01K 2217/075 (2013.01); A01K 2217/15 (2013.01); A01K 2227/108 (2013.01); A01K 2267/01 (2013.01); A01K 2267/02 (2013.01); A61K 2039/505 (2013.01); C07K 16/44 (2013.01); C07K 2317/10 (2013.01); C07K 2317/20 (2013.01); C07K 2317/41 (2013.01); C07K 2317/734 (2013.01); C12N 9/0071 (2013.01); C12N 9/1048 (2013.01); C12N 2760/14111 (2013.01)] 2 Claims
 
1. A method for producing polyclonal antibodies, comprising the steps of:
a) providing a genetically altered pig lacking:
(i) a gene encoding a functional cytidine-5′-monophosphate N-acetyl neuraminic acid hydrolase (CMAH) and (ii) a gene encoding a functional α-(1,3)-galactosyltransferase;
b) immunizing said genetically altered pig against at least one non human biological pathogen(s) towards a human, or against at least one peptidoglycan derived from said pathogen(s); and
c) collecting the antibodies having improved Complement Dependent Cytotoxicity (CDC) activity contained in a body fluid of said genetically altered pig of step b),
said biological pathogen, or the peptidoglycan derived from said pathogen, towards a human, being a bacteria or a virus,
wherein the polyclonal antibodies having an improved CDC activity, as compared to:
polyclonal antibodies obtained from the same method from a wildtype pig, wherein said wildtype pig comprises (i) a gene encoding a functional cytidine-5′-monophosphate N-acetyl neuraminic acid hydrolase (CMAH) and (ii) a gene encoding a functional α-(1,3)-galactosyltransferase (WT CMAH+/GGTA1+ pig), and
polyclonal antibodies obtained through the same method from a pig which comprises only one among (i) a gene encoding a functional cytidine-5′-monophosphate N-acetyl neuraminic acid hydrolase (CMAH) (CMAH−/GGTA1+ pig) or (ii) a gene encoding a functional α-(1,3)-galactosyltransferase (CMAH+/GGTA1− pig).